S. Duvvuri

发表

Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences

P. Tobler, E. Fehr, Alexander Soutschek, 2020, Biological Psychiatry.

In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment.

A. Mitra, U. Kompella, S. Duvvuri, 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.

A. Mitra, S. Duvvuri, D. Pal, 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine

A. Mitra, S. Duvvuri, M. Gandhi, 2003, Current eye research.

A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human

T. Nicholas, H. Barton, Y. Lu, 2017, CPT: pharmacometrics & systems pharmacology.

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated

S. Duvvuri, David L. Gray, U. S. Sohur, 2018, Neurology and Therapy.

Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.

A. Mitra, S. Duvvuri, N. Mandava, 2007, International journal of pharmaceutics.

The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.

R. Mailman, P. Eslinger, Xuemei Huang, 2020, Journal of Parkinson's disease.

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

E. Liu, H. Brashear, M. Delnomdedieu, 2016, Alzheimer's Research & Therapy.

Microdialysis assessment of drug delivery systems for vitreoretinal targets.

A. Mitra, S. Duvvuri, K. Rittenhouse, 2005, Advanced drug delivery reviews.

Prodrug strategies in nasal drug delivery

A. Mitra, I. Pezron, S. Duvvuri, 2002 .

Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio

T. Nicholas, R. Obach, L. Tremaine, 2018, Drug Metabolism and Disposition.

Bioreversion and Oral Bioavailability of the l‐Valine Dipeptide Ester Prodrug of Acyclovir, Val‐Valacyclovir, in Sprague‐Dawley Rats

S. Majumdar, A. Mitra, S. Duvvuri, 2004 .

Drug Delivery to the Eye

A. Mitra, S. Duvvuri, B. Anand, 2005 .

Drug delivery to the retina: challenges and opportunities

Sridhar Duvvuri, S. Majumdar, A. Mitra, 2003, Expert opinion on biological therapy.

Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis

A. Mitra, S. Duvvuri, S. Macha, 2004, Current eye research.

Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development.

S. Majumdar, A. Mitra, S. Duvvuri, 2004, Advanced drug delivery reviews.

Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta

T. Nicholas, S. Duvvuri, O. Demin, 2017, CPT: pharmacometrics & systems pharmacology.

PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial

J. Werth, S. Duvvuri, David L. Gray, 2020, Therapeutic advances in neurological disorders.

Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson’s Disease following Oral Administration

S. Papapetropoulos, S. Duvvuri, David L. Gray, 2018, Neurodegenerative Diseases.

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson’s Disease

R. Gurrell, S. Duvvuri, N. DeMartinis, 2018, Clinical Drug Investigation.

A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia

R. Balice-Gordon, R. Kozak, E. Arce, 2019, Journal of psychopharmacology.

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

E. Liu, H. Brashear, M. Delnomdedieu, 2016, Alzheimer's Research & Therapy.

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

J. Krystal, C. Correll, J. Renger, 2022, The Lancet.

Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir.

A. Mitra, S. Duvvuri, Kumar G. Janoria, 2005, Journal of controlled release : official journal of the Controlled Release Society.

Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data

Hugo Geerts, Timothy Nicholas, Klaus Romero, 2020, Clinical pharmacology and therapeutics.

Effect of Polymer Blending on the Release of Ganciclovir from PLGA Microspheres

A. Mitra, S. Duvvuri, Kumar Gaurav Janoria, 2006, Pharmaceutical Research.

Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure–response analysis

S. Duvvuri, N. Tsamandouras, S. Riley, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Role of metabolism in ocular drug delivery.

S. Majumdar, A. Mitra, S. Duvvuri, 2004, Current drug metabolism.

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity

Christopher H. Chatham, G. Honey, R. Balice-Gordon, 2020, The international journal of neuropsychopharmacology.

Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease

R. Mailman, P. Eslinger, Xuemei Huang, 2023, Biomolecules.

Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial

Hugo Geerts, Timothy Nicholas, Robert Carr, 2013 .

The D 1 /D 5 dopamine partial agonist PF-06412562 in advanced stage Parkinson’s disease: a feasibility study

R. Mailman, P. Eslinger, Xuemei Huang, 2021 .

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

R. Pahwa, R. Hauser, S. Isaacson, 2023, Clinical parkinsonism & related disorders.

In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects

P. Fazio, O. Vitolo, C. Halldin, 2017, Neuropharmacology.

Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.

D. Stone, J. Renger, S. Duvvuri, 2021, The Journal of clinical investigation.

A randomized, double-blind, sponsor-unblinded, placebo- and positive-controlled study to evaluate the effects of single oral administrations of PF-04995274 on scopolamine-induced deficits in cognitive function in healthy adults

D. Raunig, S. Duvvuri, Tracey L. Rapp, 2012, Alzheimer's & Dementia.

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease

E. Bézard, R. Kozak, S. Duvvuri, 2023, CNS & neurological disorders drug targets.